Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

ourth quarter 2007; however, our original schedule of completing all three current Phase III trials by the end of 2007 has been postponed.

Phase III Products

We completed enrollment and the original protocol for the Phase III trial for high-dosage (36,000 IU) EPIAO with positive results. However, to ensure the safety of the product, the clinical centers have extended the post- treatment observation period due to concerns with higher hemoglobin levels caused by ESAs (Erythropoiesis-Stimulating Agents) in the United States. We fully support the additional observation period and remain confident in the overall safety and efficacy of the product and expect filing with SFDA in Q3 of 2008.

The initial results of the Phase III trial for TPIAO for the treatment of idiopathic thrombocytopenic purpura (ITP) demonstrated excellent efficacy and a high safety profile based on our data to date. Enrollment has been completed, but we experienced a higher than expected drop-off rate (patients left the hospital before the required observation time) due to the protocol setting employed by the clinical centers. As a result, more cases are required. We expect completion of replenished cases in Q3 of 2008 and filing with SFDA in Q4 of 2008.

We completed enrollment for the Phase III trial for NuLeusin, our second generation IL-2, with positive results based on our data to date. During the trial, the number of cases enrolled increased from our original plan and as a result, these additional cases are still in the observation period, which we expect will conclude in the second quarter 2008.

Early Stage Products

We completed efficacy and pharmacokinetics studies for NuPIAO, our second- generation EPO product, with the toxicology study currently underway. We expect to submit the application for clinical trial in the second half of 2008.

Our first humanized monoclonal antibody (mAb) in development, anti-TNF mAb (SSS07), completed characterizatio
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem ... ("Cordlife"), a multi-product healthcare company catering to the mother and child ... assisting patients across the PRC, Singapore , ... India , the Philippines and ...
(Date:7/23/2014)... 23, 2014 Astra Nova ... comprehensive consultancy and pharma training services, and the ... (ACRES) , a non-profit integrating the expertise and ... maintain a global system for clinical trials, are ... improve the expertise of industry professionals through improved ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... Dallas, Texas (PRWEB) July 22, 2014 ... the growth and maintenance of cell culture. They allow ... meet the needs of researchers in drug discovery and ... extensively used in mAb production, iPSC research, cryobanking, cell-based ... and reduce contamination risk. , Analysts forecast the ...
Breaking Biology Technology:China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4
... (NYSE:,DHR) announced that Executive Vice President and Chief ... the Robert W. Baird Industrial,Conference in Chicago, IL ... CST.,The audio will be simultaneously webcast on ... manufacturer of Professional,Instrumentation, Medical Technologies, Industrial Technologies and ...
... 4 Cambrex,Corporation (NYSE: CBM ) reports third quarter 2008 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased 3.2% (-1.7% ... 2007. -- Adjusted EBITDA for the quarter was up $1.7 ... last year. -- Debt, net of cash was $92.0 million ...
... PRGO ; TASE) today announced that its Board of ... on December 16, 2008 to,shareholders of record on November ... represents a ten percent increase over $0.05 per share,paid ... a leading global healthcare supplier that develops,manufactures and distributes ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/23/2014)... July 23, 2014 BioCatch, the ... announced today it has been named in Gartner,s Market ... Guide replaces Gartner,s well-known Magic Quadrant for Web Fraud ... as one of several vendors to deliver passive biometric ... become a standard feature of at least 30% of ...
(Date:7/23/2014)... increase in temperature around the world by 2050, according ... Panel on Climate Change (IPCC), may be advantageous to ... in the growth of forage plants such as ... grazing in tropical countries such as Brazil., The conclusion ... the Department of Biology at the Ribeiro Preto Faculty ...
(Date:7/23/2014)... bacterial group called SUP05 will play an increasingly important ... oceans as oxygen minimum zones expand, according to research ... National Academy of Sciences . , University of British ... fjord, Canada,s Saanich Inlet, to chart how microbial community ... study paints a very detailed picture of how SUP05 ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... experts have been calling for an improved database that ... conservation strategies. Botanists at the University of Bonn have ... the publication, in the Journal of Biogeography, of a ... arranged in 867 zones, known as ecoregions. "This makes ...
... Clinic researchers have found that the cause of chronic sinus ... not in the nasal and sinus tissue targeted by standard ... of Journal of Allergy and Clinical Immunology and are ... been thought worldwide about the origin of chronic sinus infection: ...
... A team of researchers at the Universitat Autònoma de ... The sensors have the same size and thickness as ... DNA chains to several minutes or a few hours, ... to many different tasks, ranging from paternity tests and ...
Cached Biology News:Scientists map the world for nature conservation 2Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show It's Snot 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... XpressPack™ Colorimetric Detection System is intended for ... DNA generated by an in-house validated in ... target of interest. • ... is a hybridization capture assay designed to ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Biology Products: